Business Description
Race Oncology Ltd
ISIN : AU000000RAC3
Compare
Compare
Traded in other countries / regions
RAC.AustraliaFN3.GermanyRAONF.USA IPO Date
2024-07-17Description
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -30.8 | |||||
| 3-Year EPS without NRI Growth Rate | -20.5 | |||||
| 3-Year FCF Growth Rate | -17.2 | |||||
| 3-Year Book Growth Rate | 4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.56 | |||||
| 9-Day RSI | 38.55 | |||||
| 14-Day RSI | 39.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.32 | |||||
| Quick Ratio | 9.32 | |||||
| Cash Ratio | 9.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | -2.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -64.54 | |||||
| ROA % | -61.02 | |||||
| ROIC % | -405.51 | |||||
| 3-Year ROIIC % | 788.77 | |||||
| ROC (Joel Greenblatt) % | -760.03 | |||||
| ROCE % | -87.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 13.84 | |||||
| Price-to-Tangible-Book | 17.6 | |||||
| EV-to-EBIT | -12.74 | |||||
| EV-to-EBITDA | -12.94 | |||||
| EV-to-FCF | -24.9 | |||||
| Price-to-Net-Current-Asset-Value | 17.6 | |||||
| Price-to-Net-Cash | 17.6 | |||||
| Earnings Yield (Greenblatt) % | -7.85 | |||||
| FCF Yield % | -3.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Race Oncology Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.03 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 39.53 | ||
| 14-Day ATR (€) | 0.021366 | ||
| 20-Day SMA (€) | 0.941 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.769 - 1.1014 | ||
| Shares Outstanding (Mil) | 170.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Race Oncology Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Race Oncology Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Race Oncology Ltd Frequently Asked Questions
What is Race Oncology Ltd(FRA:FN3)'s stock price today?
The current price of FRA:FN3 is €0.88. The 52 week high of FRA:FN3 is €1.10 and 52 week low is €0.77.
When is next earnings date of Race Oncology Ltd(FRA:FN3)?
The next earnings date of Race Oncology Ltd(FRA:FN3) is .
Does Race Oncology Ltd(FRA:FN3) pay dividends? If so, how much?
Race Oncology Ltd(FRA:FN3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers